Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4115320 | 0.85 | KMT2A (0.72) | KMT2AMEN1LMNATP53ATM | |
| SCHEMBL5472746 | 0.81 | KMT2A (0.67) | KMT2AMEN1LMNATP53ATM | |
| SCHEMBL5474194 | 0.80 | KMT2A (0.65) | KMT2AMEN1LMNATP53ATM | |
| SCHEMBL5466617 | 0.79 | MCL1 (0.54) | KMT2AMEN1CYP11B1CYP11B2MAPT | |
| SCHEMBL10186983 | 0.78 | MEN1 (0.69) | KMT2AMEN1MAPTTP53L3MBTL1 | |
| SCHEMBL25754850 | 0.78 | MEN1 (0.55) | KMT2AMEN1CYP11B1CYP11B2MAPT | |
| SCHEMBL665548 | 0.77 | AKR1C3 (0.74) | KMT2AMEN1MAPTLMNATP53 | |
| SCHEMBL23847011 | 0.77 | PKM (0.52) | KMT2AMEN1LMNAALDH1A1RORC | |
| SCHEMBL5475972 | 0.77 | AKR1C3 (0.66) | KMT2AMEN1MAPTLMNATP53 | |
| SCHEMBL23884826 | 0.77 | KMT2A (0.63) | KMT2AMEN1CYP11B1CYP11B2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| WO-2021188880-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | KMT2A 4864/4885MEN1 3902/4885CYP11B1 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.